Long-term Follow-up of Pure Ductal Carcinoma in situ after Breast-Conserving Surgery
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Ductal carcinoma in situ (DCIS) is a high-risk disease for the development of invasive tumors. Although it is associated with excellent prognosis, many patients undergo extensive treatment with surgery, radiation, and endocrine therapy. This study evaluated the clinical and pathologic factors associated with invasive recurrence, particularly locoregional, distant disease after breast-conserving surgery (BCS). Methods: This study included 431 patients diagnosed with pure DCIS after BCS between January 2000 and December 2008. The clinicopathological characteristics, margin status, adjuvant therapy, and duration of endocrine therapy were evaluated in hormone receptor-positive DCIS patients. Results: The median duration of follow-up was 115 months. During this period, 37 cases (8.5%) of recurrence were observed (12 in situ and 23 invasive recurrence and 2 unknown cases). There was no distant metastasis as first event. Similarly, none of the initial in situ recurrence cases developed distant metastasis while eight (32%, 8/23) developed distant metastasis after invasive recurrence. Overall recurrence was associated with young age (≤40 years) (HR: 3.60, 95% confidence interval [CI]: 1.77–7.32) and hormone receptor negativity (HR: 3.33, 95% CI: 1.52–7.29). Invasive local recurrence was independently associated with young age (≤40 years) (HR: 3.86, 95% CI: 1.50–9.96), high nuclear grade (HR: 4.46, 95% CI: 1.62–12.27) and omission of adjuvant radiotherapy (HR: 6.45, 95% CI: 1.82–22.82). Notably, duration of endocrine treatment among the hormone receptor positive patient group, was numerically shorter for recurred patients, though not statistically significant. Conclusion: Young age, high nuclear grade and absence of adjuvant radiotherapy were independently associated with an increased risk of invasive recurrence. Moreover, invasive locoregional recurrence as a first event was associated with worse outcomes, yet in situ recurrence didn’t affect overall survival. Further studies with larger sample sizes are warranted to confirm the prognostic indicators of recurrence and the optimal strategy for adjuvant therapy in this setting.
Abstract
Purpose: Ductal carcinoma in situ (DCIS) is a high-risk disease for the development of invasive tumors. Although it is associated with excellent prognosis, many patients undergo extensive treatment with surgery, radiation, and endocrine therapy. This study evaluated the clinical and pathologic factors associated with invasive recurrence, particularly locoregional, distant disease after breast-conserving surgery (BCS). Methods: This study included 431 patients diagnosed with pure DCIS after BCS between January 2000 and December 2008. The clinicopathological characteristics, margin status, adjuvant therapy, and duration of endocrine therapy were evaluated in hormone receptor-positive DCIS patients. Results: The median duration of follow-up was 115 months. During this period, 37 cases (8.5%) of recurrence were observed (12 in situ and 23 invasive recurrence and 2 unknown cases). There was no distant metastasis as first event. Similarly, none of the initial in situ recurrence cases developed distant metastasis while eight (32%, 8/23) developed distant metastasis after invasive recurrence. Overall recurrence was associated with young age (≤40 years) (HR: 3.60, 95% confidence interval [CI]: 1.77–7.32) and hormone receptor negativity (HR: 3.33, 95% CI: 1.52–7.29). Invasive local recurrence was independently associated with young age (≤40 years) (HR: 3.86, 95% CI: 1.50–9.96), high nuclear grade (HR: 4.46, 95% CI: 1.62–12.27) and omission of adjuvant radiotherapy (HR: 6.45, 95% CI: 1.82–22.82). Notably, duration of endocrine treatment among the hormone receptor positive patient group, was numerically shorter for recurred patients, though not statistically significant. Conclusion: Young age, high nuclear grade and absence of adjuvant radiotherapy were independently associated with an increased risk of invasive recurrence. Moreover, invasive locoregional recurrence as a first event was associated with worse outcomes, yet in situ recurrence didn’t affect overall survival. Further studies with larger sample sizes are warranted to confirm the prognostic indicators of recurrence and the optimal strategy for adjuvant therapy in this setting.
참고문헌 (30)
- Virnig BA, "Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes", J Natl Cancer Inst, 102, pp.170~178 (2010)
- 박은화, "Basic Facts of Breast Cancer in Korea in 2014: The 10-Year Overall Survival Progress", Journal of Breast Cancer, 20(1), pp.1~11 (2017), 한국유방암학회[DOI]
- Carlson RW, "Breast cancer. Clinical practice guidelines in oncology", J Natl Compr Canc Netw, 7, pp.122~192 (2009)
- Houghton J, "Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial", Lancet, 362, pp.95~102 (2003)
- Group EBCC, "Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group", J Clin Oncol, 24, pp.3381~3387 (2006)
- Romero L, "Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast", Am J Surg, 188, pp.371~376 (2004)
- Donker M, "Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial", J Clin Oncol, 31, pp.4054~4059 (2013)
- Roses RE, "Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death", Ann Surg Oncol, 18, pp.2873~2878 (2011)
- Narod SA, "Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ", JAMA Oncol, 1, pp.888~896 (2015)
- Wapnir IL, "Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS", J Natl Cancer Inst, 103, pp.478~488 (2011)
- Solin LJ, "Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast", Cancer, 103, pp.1137~1146 (2005)
- Silverstein MJ, "Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast", J Clin Oncol, 16, pp.1367~1373 (1998)
- 윤인영, "Mammographic Breast Density Evaluation in Korean Women Using Fully Automated Volumetric Assessment", Journal of Korean Medical Science, 31(3), pp.457~462 (2016), 대한의학회
- Vicini FA, "Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature", J Clin Oncol, 20, pp.2736~2744 (2002)
- Schouten van der Velden AP, "Local recurrences after conservative treatment of ductal carcinoma-in-situ of the breast without radiotherapy: the effect of age", Ann Surg Oncol, 13, pp.990~998 (2006)
- Rakovitch E, "Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis", Breast Cancer Res Treat, 138, pp.581~590 (2013)
- Wang SY, "Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis", Breast Cancer Res Treat, 127, pp.1~14 (2011)
- Ringberg A, "Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial", Eur J Cancer, 43, pp.291~298 (2007)
- Cuzick J, "Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK", ANZ DCIS trial, 2011, pp.12, 21~29
- Early Breast Cancer Trialists’ Collaborative G, "Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast", J Natl Cancer Inst Monogr, 2010, pp.162~177 (2010)
- Williams KE, "Molecular phenotypes of DCIS predict overall and invasive recurrence", Ann Oncol, 26, pp.1019~1025 (2015)
- Dawood S, "Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study", Breast Cancer Res Treat, 126, pp.185~192 (2011)
- Cornfield DB, "The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone", Cancer, 100, pp.2317~2327 (2004)
- 김정연, "Predictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving Surgery", Journal of Breast Cancer, 19(2), pp.185~190 (2016), 한국유방암학회
- Allred DC, "Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ : a study based on NSABP protocol B-24", J Clin Oncol, 30, pp.1268~1273 (2012)
- Mele A, "Breast-conserving surgery alone for ductal carcinoma in situ: factors associated with increased risk of local recurrence", Ann Surg Oncol, 24, pp.1221~1226 (2017)
- Mathew J, "Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situ", Breast, 31, pp.181~185 (2017)
- Fisher B, "Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17", J Clin Oncol, 16, pp.441~452 (1998)
- Bannani S, "The locoregional recurrence post-mastectomy for ductal carcinoma in situ: Incidence and risk factors", Breast, 24, pp.608~612 (2015)
- Buist DS, "Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer", Breast Cancer Res Treat, 124, pp.863~873 (2010)